What it's for (Indications)
- Ranitidine, a histamine H2-receptor antagonist, was historically indicated for the short-term treatment of active duodenal ulcer, typically for up to eight weeks, and for active benign gastric ulcer.
- It was also widely used for the management of gastroesophageal reflux disease (GERD) and erosive esophagitis, offering symptomatic relief and promoting healing of esophageal lesions caused by gastric acid reflux.
- Furthermore, ranitidine found application in the long-term maintenance therapy for healed duodenal ulcers to prevent recurrence and was a primary treatment for pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, where excessive gastric acid secretion required potent inhibition.
- Its mechanism of action allowed for effective control of gastric acidity, thereby alleviating symptoms and aiding in mucosal healing in various acid-related disorders.
- However, it is imperative to note that despite these former indications, ranitidine products have been withdrawn from the market globally due to safety concerns, making these indications no longer relevant for current clinical practice or prescribing.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Historically, the dosage of ranitidine varied significantly depending on the specific condition being treated, the patient's age, and their renal function. For active duodenal ulcer, typical adult dosing was 150 mg twice daily or 300 mg once daily at bedtime for 4 to 8 weeks. For maintenance therapy, a lower dose of 150 mg once daily at bedtime was common. In the treatment of gastroesophageal reflux disease (GERD), dosages could range from 150 mg twice daily to 150 mg four times daily, or 300 mg twice daily for more severe cases or erosive esophagitis. Pediatric dosages were typically weight-based, often starting at 2-4 mg/kg twice daily for conditions like GERD. For pathological hypersecretory conditions such as Zollinger-Ellison syndrome, dosages were individualized and often higher, sometimes reaching 6 g/day. Renal impairment necessitated dosage adjustments; for patients with creatinine clearance less than 50 mL/min, the recommended dose was typically 150 mg every 24 hours. All historical dosage guidelines are now superseded by the drug's global market withdrawal. |
Safety & Warnings
Common Side Effects
- When ranitidine was commercially available, its side effect profile was generally considered favorable, with most adverse reactions being mild and transient.
- Common side effects included headache, which was frequently reported, along with gastrointestinal disturbances such as nausea, vomiting, abdominal pain, diarrhea, and constipation.
- Less common adverse effects involved the central nervous system (CNS), particularly in elderly patients or those with severe renal or hepatic impairment, and could manifest as dizziness, insomnia, confusion, agitation, depression, or hallucinations.
- Hematologic effects such as leukopenia, thrombocytopenia, and, rarely, aplastic anemia, were reported.
- Hepatic adverse events included transient elevations in liver enzymes, hepatitis with or without jaundice, and, in very rare instances, hepatocellular, canalicular, or mixed cholestatic-hepatocellular forms of liver damage.
- Hypersensitivity reactions, ranging from rash and pruritus to more severe manifestations like bronchospasm, fever, and anaphylaxis, were also noted.
- Cardiovascular effects, such as bradycardia or tachycardia, were rare.
- These side effects are retrospective observations from its period of active prescription.
Serious Warnings
- Black Box Warning: SERIOUS WARNING: MARKET WITHDRAWAL DUE TO POTENTIAL CARCINOGENIC RISK. All ranitidine products, encompassing both oral (e.g., Peptinil Syrup) and injectable formulations, were subject to a global market withdrawal initiated by the U.S. Food and Drug Administration (FDA) in April 2020. This decisive action followed extensive investigations that revealed certain ranitidine products could contain unacceptable and escalating levels of N-nitrosodimethylamine (NDMA), a probable human carcinogen. NDMA levels were found to increase over time and when ranitidine products were stored at temperatures higher than room temperature, posing a significant public health concern. Based on robust animal studies, NDMA is classified as a probable human carcinogen. Due to the confirmed and potential risks associated with these NDMA impurities, healthcare professionals are strongly advised to cease prescribing and dispensing ranitidine-containing medications. Patients currently using any ranitidine product should be counseled to discontinue use immediately and to consult their healthcare provider to discuss alternative, safer treatment options for their medical conditions. The potential carcinogenic risks associated with continued use of ranitidine products far outweigh any historical therapeutic benefits, rendering its use unsafe and strongly discouraged.
- Beyond the critical market withdrawal due to NDMA contamination (detailed in the Black Box Warning), several warnings were historically associated with ranitidine.
- Prior to initiating ranitidine therapy for dyspeptic symptoms, it was crucial to exclude the presence of gastric malignancy, as symptomatic improvement might inadvertently mask an underlying carcinoma.
- Caution was advised in patients with impaired renal or hepatic function, as reduced drug clearance could lead to accumulation and increased risk of adverse effects, necessitating dosage adjustments.
- Elderly patients were identified as being potentially more susceptible to central nervous system side effects, warranting careful monitoring.
- Ranitidine was contraindicated in patients with a history of acute porphyria, as it has been linked to the precipitation of acute porphyric attacks.
- Long-term acid suppression with H2-receptor antagonists, including ranitidine, has been suggested to potentially increase the risk of community-acquired pneumonia and may reduce the absorption of vitamin B12, particularly in patients predisposed to deficiency.
- Interactions with drugs requiring an acidic gastric environment for optimal absorption were also a concern, as ranitidine could significantly elevate gastric pH.
- These warnings remain relevant for understanding ranitidine's pharmacological profile, despite its market unavailability.
How it Works (Mechanism of Action)
Ranitidine exerts its therapeutic effects by acting as a highly selective, competitive, and reversible antagonist of histamine at the H2-receptors found on the parietal cells of the stomach. Histamine is a primary stimulant of gastric acid secretion, binding to these H2-receptors to activate the proton pump. By blocking the binding of histamine, ranitidine effectively inhibits both basal (resting) gastric acid secretion and acid secretion stimulated by various physiological agonists, including histamine itself, gastrin, and acetylcholine. This reduction in acid output leads to a significant decrease in the acidity of the gastric lumen. The diminished acid levels contribute to the relief of symptoms associated with acid-related disorders and promote the healing of ulcers and erosions in the esophagus and stomach. Unlike some other anti-ulcer medications, ranitidine does not possess anticholinergic properties and exhibits minimal interaction with the cytochrome P450 enzyme system, distinguishing it from earlier H2-receptor antagonists like cimetidine, which had more pronounced drug interaction profiles.